<DOC>
	<DOCNO>NCT01475292</DOCNO>
	<brief_summary>RV568 develop possible treatment disease smoke related lung disease ( also know Chronic Obstructive Pulmonary Disease - COPD ) asthma . The main purpose study examine safety RV568 COPD patient . Two dose strength RV568 placebo test study , give inhale liquid suspension nebuliser day 2 week .</brief_summary>
	<brief_title>A Study Investigate How Safe Well Tolerated RV568 Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Male female age 4075 year inclusive time signing informed consent . Capable give write informed consent , include compliance requirement restriction list consent form . COPD diagnosis : Subjects diagnosis COPD define American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) guideline , symptom compatible COPD least 1 year prior screen . Severity Disease : subject conform current severity classification GOLD Stage II/III disease term postbronchodilator spirometry screening ( Postsalbutamol FEV1/FVC ratio ≤ 0.70 postsalbutamol FEV1 ≥ 40 % ≤ 80 % predict normal value calculate use ECCS reference equation ) Demonstrated ability use Ineb AAD system screen . Subject current previous smoker smoke history ≥ 10 pack year A history lifethreatening COPD include Intensive Care Unit admission and/or require intubation A history &gt; 1 hospitalisation COPD previous 2 year prior screen . Evidence cor pulmonale clinically significant pulmonary hypertension chronic ( opinion Investigator ) use oxygen . Upper low respiratory tract infection , include exacerbation COPD , within 6 week screen . Other respiratory disorder : Subjects current diagnosis asthma , active tuberculosis , lung cancer , bronchiectasis , sarcoidosis , lung fibrosis , interstitial lung disease active pulmonary disease . Subjects history chronic disease include , limited , sleep apnoea , cardiovascular , endocrine , neurological , hepatic , gastrointestinal , renal , hematological , urological , immunological , ophthalmic disease Investigator believe clinically significant . Previous lung resection lung reduction surgery . Pregnant nursing female . Any abnormal clinically significant ECG laboratory value Investigator considers would put subject risk participation . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator sponsor representative agree unlikely introduce additional risk factor interfere study procedure . ALT &gt; 2 x ULN screen visit . A positive prestudy Hepatitis B surface antigen , positive Hepatitis C antibody result , positive test HIV antibody screen visit ( within 3 month prior screen ) . Positive test drug abuse screen satisfactorily explain prescription history ( e.g. , recent use codeine tablet ) . History alcohol abuse within previous 6 month Has major surgery , ( require general anesthesia ) within 6 week screen visit , fully recover surgery , plan surgery end study Participated clinical study NCE within 3 month , study market drug within 1 month ( within 5 halflives NCE market drug , whichever long ) first dose ; participate 4 study previous 12 month . A disclosed history , one know Investigator , significant noncompliance previous investigational study prescribe medication . Allergy active inactive ingredient study medication , history drug , allergy , opinion Investigator RespiVert medical monitor , would contraindicate participation . Donation blood excess 500 mL within 3 month period prior dose , study participation would result blood loss excess 500 mL 3 month period . Subject mentally legally incapacitate . Has condition take medication , opinion Investigator , would make participation best interest ( i.e. , compromise wellbeing ) subject could prevent , limit , confound protocolspecified assessment . Is employee Investigator study site , direct involvement propose study study direction investigator study site , well family member employee Investigator . Any reason Investigator considers make subject unsuitable participate . Subject history unstable , uncontrolled hypertension , diagnose hypertension last 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>COPD</keyword>
</DOC>